{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:22:16Z","timestamp":1792725736115,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100032703","name":"BridgeBio Pharma, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032703","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40119-025-00443-3","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:25:18Z","timestamp":1766147118000},"page":"59-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Outcomes Among Patients in the United States Receiving Tafamidis for Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-0248","authenticated-orcid":false,"given":"Daniel P.","family":"Judge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Udall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Lamarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Nagelhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh Dung","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"1","key":"443_CR1","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1262","volume":"18","author":"D Brito","year":"2023","unstructured":"Brito D, Albrecht FC, de Arenaza DP, et al. World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM). Glob Heart. 2023;18(1):59.","journal-title":"Glob Heart"},{"issue":"5","key":"443_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamacardio.2024.5221","volume":"10","author":"A Porcari","year":"2025","unstructured":"Porcari A, Razvi Y, Cappelli F, et al. Clinical phenotype and prognosis of asymptomatic patients with transthyretin cardiac amyloid infiltration. JAMA Cardiol. 2025;10(5):437\u201345.","journal-title":"JAMA Cardiol"},{"issue":"22","key":"443_CR3","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"443_CR4","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076\u2013126.","journal-title":"J Am Coll Cardiol"},{"key":"443_CR5","doi-asserted-by":"publisher","unstructured":"Writing Committee, Kittleson MM, Ambardekar AV, et al. Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. J Am Coll Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.jacc.2025.09.004","DOI":"10.1016\/j.jacc.2025.09.004"},{"key":"443_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/VHRM.S295376","volume":"17","author":"G Korosoglou","year":"2021","unstructured":"Korosoglou G, Giusca S, Andre F, et al. Diagnostic work-up of cardiac amyloidosis using cardiovascular imaging: current standards and practical algorithms. Vasc Health Risk Manag. 2021;17:661\u201373.","journal-title":"Vasc Health Risk Manag"},{"key":"443_CR7","unstructured":"VYNDAMAX\u00ae (tafamidis) [package insert]. 2023."},{"issue":"11","key":"443_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.; for the ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"key":"443_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3696","author":"T Damy","year":"2025","unstructured":"Damy T, Wang R, Maurer MS, Gillmore JD, Fontana M. Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage. Eur J Heart Fail. 2025. https:\/\/doi.org\/10.1002\/ejhf.3696.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"443_CR10","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.cardfail.2025.01.015","volume":"31","author":"MS Maurer","year":"2025","unstructured":"Maurer MS. A question in the era of multiple effective therapies for transthyretin amyloid cardiomyopathy (ATTR-CM): is transthyretin biology a driver of disease progression? J Card Fail. 2025;31(4):746\u20137.","journal-title":"J Card Fail"},{"issue":"3","key":"443_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","volume":"31","author":"P Garcia-Pavia","year":"2025","unstructured":"Garcia-Pavia P, Kristen AV, Drachman B, et al.; on behalf of the THAOS investigators. Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). J Card Fail. 2025;31(3):525\u201333.","journal-title":"J Card Fail"},{"issue":"14","key":"443_CR12","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","volume":"83","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Cappelli F, Emdin M, et al. Stratifying disease progression in patients with cardiac ATTR amyloidosis. J Am Coll Cardiol. 2024;83(14):1276\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"443_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101667","volume":"48","author":"A Ghoneem","year":"2023","unstructured":"Ghoneem A, Bhatti AW, Khadke S, et al. Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure. Curr Probl Cardiol. 2023;48(6):101667.","journal-title":"Curr Probl Cardiol"},{"issue":"14","key":"443_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/heartjnl-2024-324826","volume":"111","author":"D Bampatsias","year":"2025","unstructured":"Bampatsias D, Wardhere A, Zeldin L, et al. Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis. Heart. 2025;111(14):651\u20136.","journal-title":"Heart"},{"issue":"30","key":"443_CR15","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799\u2013806.","journal-title":"Eur Heart J"},{"key":"443_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2018.12.069","volume":"280","author":"S Kasahara","year":"2019","unstructured":"Kasahara S, Sakata Y, Nochioka K, et al. Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases. Int J Cardiol. 2019;280:184\u20139.","journal-title":"Int J Cardiol"},{"key":"443_CR17","unstructured":"R Development Core Team. R Foundation for Statistical Computing; 2010. R: A language and environment for statistical computing. 2010."},{"issue":"1","key":"443_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1\u201322.","journal-title":"J Stat Softw"},{"issue":"5","key":"443_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v039.i05","volume":"39","author":"N Simon","year":"2011","unstructured":"Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox\u2019s proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1\u201313.","journal-title":"J Stat Softw"},{"issue":"5","key":"443_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/jamacardio.2016.1878","volume":"1","author":"DM Flatt","year":"2016","unstructured":"Flatt DM, Brown MC, Mizeracki AM, King BJ, Weber KT. Mineralocorticoid receptor antagonists in the management of heart failure and resistant hypertension: a review. JAMA Cardiol. 2016;1(5):607\u201312.","journal-title":"JAMA Cardiol"},{"issue":"10458","key":"443_CR21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024;404(10458):1119\u201331.","journal-title":"Lancet"},{"issue":"10","key":"443_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258949","volume":"16","author":"A Jonsson Holmdahl","year":"2021","unstructured":"Jonsson Holmdahl A, Norberg H, Valham F, Bergdahl E, Lindmark K. Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function. PLoS ONE. 2021;16(10):e0258949.","journal-title":"PLoS ONE"},{"issue":"9","key":"443_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jchf.2022.06.006","volume":"10","author":"T Martyn","year":"2022","unstructured":"Martyn T, Saef J, Dey AR, et al. Racial and genetic differences in presentation of transthyretin amyloid cardiomyopathy with impaired left ventricular function. JACC Heart Fail. 2022;10(9):689\u201391.","journal-title":"JACC Heart Fail"},{"issue":"3","key":"443_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jaccao.2024.05.001","volume":"6","author":"B Shankar","year":"2024","unstructured":"Shankar B, Yanek L, Jefferson A, et al. Race and socioeconomic status impact diagnosis and clinical outcomes in transthyretin cardiac amyloidosis. JACC CardioOncol. 2024;6(3):454\u201363.","journal-title":"JACC CardioOncol"},{"issue":"2","key":"443_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"443_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33\u201344.","journal-title":"N Engl J Med"},{"issue":"12","key":"443_CR27","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/ejhf.2646","volume":"24","author":"RK Patel","year":"2022","unstructured":"Patel RK, Ioannou A, Razvi Y, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis. Eur J Heart Fail. 2022;24(12):2355\u201363.","journal-title":"Eur J Heart Fail"},{"key":"443_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12170-021-00670-y","author":"G Spencer-Bonilla","year":"2021","unstructured":"Spencer-Bonilla G, Njoroge JN, Pearson K, Witteles RM, Aras MA, Alexander KM. Racial and ethnic disparities in transthyretin cardiac amyloidosis. Curr Cardiovasc Risk Rep. 2021. https:\/\/doi.org\/10.1007\/s12170-021-00670-y.","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"3","key":"443_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","volume":"7","author":"A Masri","year":"2025","unstructured":"Masri A, Bhattacharya P, Medoff B, et al. A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy. JACC CardioOncol. 2025;7(3):282\u201393.","journal-title":"JACC CardioOncol"},{"issue":"8","key":"443_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102549","volume":"13","author":"G Sinigiani","year":"2025","unstructured":"Sinigiani G, Sanna GD, Aimo A, et al. Outcome and disease progression in NYHA functional class\u00a0I and II patients with wild-type transthyretin cardiomyopathy treated with tafamidis. JACC Heart Fail. 2025;13(8):102549.","journal-title":"JACC Heart Fail"},{"key":"443_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3540","author":"L Zeldin","year":"2024","unstructured":"Zeldin L, Eichler JBS, Teruya SL, et al. Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2024. https:\/\/doi.org\/10.1002\/ejhf.3540.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"443_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/1062860606288774","volume":"21","author":"PT Tyree","year":"2006","unstructured":"Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance claims data for utilization analysis. Am J Med Qual. 2006;21(4):269\u201375.","journal-title":"Am J Med Qual"},{"issue":"16","key":"443_CR33","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368.","journal-title":"Eur Heart J"},{"issue":"1","key":"443_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"443_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1161\/CIRCHEARTFAILURE.113.000895","volume":"7","author":"JM Testani","year":"2014","unstructured":"Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7(2):261\u201370.","journal-title":"Circ Heart Fail"},{"key":"443_CR36","volume-title":"Michigan medicine clinical care guidelines. Michigan medicine inpatient diuretic guideline for patients with acute decompensated heart failure","author":"MC Konerman","year":"2022","unstructured":"Konerman MC, Bozaan DA, Adie S, et al. Michigan Medicine clinical care guidelines. Michigan Medicine inpatient diuretic guideline for patients with acute decompensated heart failure. Ann Arbor: Michigan Medicine University of Michigan \u00a9 Regents of the University of Michigan; 2022."},{"issue":"15","key":"443_CR37","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","volume":"110","author":"P Bettencourt","year":"2004","unstructured":"Bettencourt P, Azevedo A, Pimenta J, Fri\u00f5es F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110(15):2168\u201374.","journal-title":"Circulation"},{"issue":"7","key":"443_CR38","first-page":"476","volume":"15","author":"J Perez-Downes","year":"2018","unstructured":"Perez-Downes J, Palacio C, Ibrahim S, Shelley P, Miller A, Reddy P. Prognostic utility of NT-proBNP greater than 70,000 pg\/mL in patients with end stage renal disease. J Geriatr Cardiol. 2018;15(7):476\u20138.","journal-title":"J Geriatr Cardiol"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00443-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:26:36Z","timestamp":1773509196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00443-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00443-3","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Daniel P. Judge: Consultancy fees from Alnylam Pharmaceuticals, Attralus, Bayer, BridgeBio Pharma, Inc., Cytokinetics, Lexeo Therapeutics, Novo Nordisk, Rocket Pharmaceuticals, and Tenaya Therapeutics. Margarita Udall and Andrew M. Rosen: Employees and stockholders of BridgeBio Pharma, Inc. Margarita Udall is a stockholder of Pfizer, Inc. Neil Lamarre, Elizabeth Nagelhout, and Hanh Dung Dao: Contractors for BridgeBio Pharma, Inc. Mathew S. Maurer: for NIH R01HL139671 and R01AG081582-01, Alnylam Pharmaceuticals, BridgeBio Pharma, Inc. (formerly Eidos Therapeutics), Ionis Pharmaceuticals, Pfizer Inc., and Prothena Biosciences; consultant or advisor for Akcea Therapeutics, Alnylam Pharmaceuticals, AstraZeneca, Attralus, BridgeBio Pharma, Inc. (formerly Eidos Therapeutics), Intellia Therapeutics, Ionis Pharmaceuticals, Novo Nordisk, and Pfizer, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Because the Komodo Healthcare Map database contains anonymized, de-identified data that complies with the Health Insurance Portability and Accountability Act, and this study did not involve the collection, use, or transmittal of individually identifiable data, the study did not require ethics committee review or informed consent. Permission was obtained to access and analyze data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}